118 related articles for article (PubMed ID: 26922821)
21. Identifying Patients at High Risk of Loss of Response to Infliximab Maintenance Therapy in Paediatric Crohn's Disease.
Dupont-Lucas C; Sternszus R; Ezri J; Leibovitch S; Gervais F; Amre D; Deslandres C
J Crohns Colitis; 2016 Jul; 10(7):795-804. PubMed ID: 26822611
[TBL] [Abstract][Full Text] [Related]
22. Implications of Infliximab Treatment Failure and Influence of Personalized Treatment on Patient-reported Health-related Quality of Life and Productivity Outcomes in Crohn's Disease.
Steenholdt C; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
J Crohns Colitis; 2015 Nov; 9(11):1032-42. PubMed ID: 26245216
[TBL] [Abstract][Full Text] [Related]
23. Mean Platelet Volume in Crohn's Disease Patients Predicts Sustained Response to a 52-Week Infliximab Therapy: A Pilot Study.
Sobolewska A; Włodarczyk M; Stec-Michalska K; Fichna J; Wiśniewska-Jarosińska M
Dig Dis Sci; 2016 Feb; 61(2):542-9. PubMed ID: 26441277
[TBL] [Abstract][Full Text] [Related]
24. Predictive value of mucosal TNF-alpha transcripts in steroid-refractory Crohn's disease patients receiving intensive immunosuppressive therapy.
Schmidt C; Giese T; Hermann E; Zeuzem S; Meuer SC; Stallmach A
Inflamm Bowel Dis; 2007 Jan; 13(1):65-70. PubMed ID: 17206641
[TBL] [Abstract][Full Text] [Related]
25. Costs of care for Crohn's disease following the introduction of infliximab: a single-centre UK experience.
Sprakes MB; Ford AC; Suares NC; Warren L; Greer D; Donnellan CF; Jennings JS; Everett SM; Hamlin PJ
Aliment Pharmacol Ther; 2010 Dec; 32(11-12):1357-63. PubMed ID: 21050238
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy and safety of treatment with infliximab in Crohn's disease-the experience of single center in Korea].
Choi KD; Song HJ; Kim JS; Jung HC; Song IS
Korean J Gastroenterol; 2005 Jul; 46(1):48-55. PubMed ID: 16030404
[TBL] [Abstract][Full Text] [Related]
27. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
[TBL] [Abstract][Full Text] [Related]
28. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania.
Gheorghe L; Gheorghe C; Badea M; Vădan R; Pârvulescu I; Toader C; Tugui L; Papuc O; Ionescu R; Preda C; Călin I; Diculescu M
Rom J Gastroenterol; 2003 Mar; 12(1):7-13. PubMed ID: 12673373
[TBL] [Abstract][Full Text] [Related]
29. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
[TBL] [Abstract][Full Text] [Related]
30. SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB.
Bau M; Zacharias P; Ribeiro DA; Boaron L; Steckert Filho A; Kotze PG
Arq Gastroenterol; 2017 Dec; 54(4):328-332. PubMed ID: 28954043
[TBL] [Abstract][Full Text] [Related]
31. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease.
Kobayashi T; Okamoto S; Hisamatsu T; Kamada N; Chinen H; Saito R; Kitazume MT; Nakazawa A; Sugita A; Koganei K; Isobe K; Hibi T
Gut; 2008 Dec; 57(12):1682-9. PubMed ID: 18653729
[TBL] [Abstract][Full Text] [Related]
32. [Improvement of bone metabolism after infliximab therapy in Crohn's disease].
Miheller P; Muzes G; Zágoni T; Tóth M; Rácz K; Tulassay Z
Orv Hetil; 2005 Jul; 146(28):1477-80. PubMed ID: 16130441
[TBL] [Abstract][Full Text] [Related]
33. Higher Rates of Dose Optimisation for Infliximab Responders in Ulcerative Colitis than in Crohn's disease.
O'Donnell S; Stempak JM; Steinhart AH; Silverberg MS
J Crohns Colitis; 2015 Oct; 9(10):830-6. PubMed ID: 26116556
[TBL] [Abstract][Full Text] [Related]
34. A Matrix-based Model Predicts Primary Response to Infliximab in Crohn's Disease.
Billiet T; Papamichael K; de Bruyn M; Verstockt B; Cleynen I; Princen F; Singh S; Ferrante M; Van Assche G; Vermeire S
J Crohns Colitis; 2015 Dec; 9(12):1120-6. PubMed ID: 26351386
[TBL] [Abstract][Full Text] [Related]
35. The role of ABO blood groups in Crohn's disease and in monitoring response to infliximab treatment.
Yu Q; Wang L; Zhang S; Feng T; Li L; Chen B; Chen M
Blood Transfus; 2016 Sep; 14(5):460-4. PubMed ID: 27136434
[TBL] [Abstract][Full Text] [Related]
36. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
Ferrante M; Colombel JF; Sandborn WJ; Reinisch W; Mantzaris GJ; Kornbluth A; Rachmilewitz D; Lichtiger S; D'Haens GR; van der Woude CJ; Danese S; Diamond RH; Oortwijn AF; Tang KL; Miller M; Cornillie F; Rutgeerts PJ;
Gastroenterology; 2013 Nov; 145(5):978-986.e5. PubMed ID: 23954314
[TBL] [Abstract][Full Text] [Related]
37. Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy.
Leal RF; Planell N; Kajekar R; Lozano JJ; Ordás I; Dotti I; Esteller M; Masamunt MC; Parmar H; Ricart E; Panés J; Salas A
Gut; 2015 Feb; 64(2):233-42. PubMed ID: 24700437
[TBL] [Abstract][Full Text] [Related]
38. A case of Crohn's disease that developed anti-infliximab and anti-adalimumab antibodies.
Takahashi K; Fujimoto T; Shioya M; Nishida A; Bamba S; Inatomi O; Imaeda H; Kitoh K; Andoh A
Clin J Gastroenterol; 2015 Apr; 8(2):88-91. PubMed ID: 25795267
[TBL] [Abstract][Full Text] [Related]
39. The influence of anti-TNF therapy on CD31 and VEGF expression in colonic mucosa of Crohn's disease patients in relation to mucosal healing.
Eder P; Lykowska-Szuber L; Iwanik K; Krela-Kazmierczak I; Stawczyk-Eder K; Majewski P; Linke K; Kay EW; Wozniak A
Folia Histochem Cytobiol; 2016; 54(2):75-80. PubMed ID: 27270504
[TBL] [Abstract][Full Text] [Related]
40. An Increased Serum N-Terminal Telopeptide of Type I Collagen, a Biochemical Marker of Increased Bone Resorption, Is Associated with Infliximab Therapy in Patients with Crohn's Disease.
Sugimoto K; Ikeya K; Iida T; Kawasaki S; Arai O; Umehara K; Watanabe F; Tani S; Oishi S; Osawa S; Yamamoto T; Hanai H
Dig Dis Sci; 2016 Jan; 61(1):99-106. PubMed ID: 26254083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
